nsclc
However, the benefits of these agents are not uniform across the spectrum of nsclc, and optimizing their utility requires some degree of subgrouping of nsclc by the presence or absence of certain biomarkers.The biomarkers of current or imminent value are EGFR and KRAS mutational status, ALK rearrangements, and MET immunohistochemistry.
However, the benefits of these agents are not uniform across the spectrum of <span class="disease" id="22787409-3-77-82">nsclc</span>, and optimizing their utility requires some degree of subgrouping of <span class="disease" id="22787409-3-152-157">nsclc</span> by the presence or absence of certain biomarkers.The biomarkers of current or imminent value are EGFR and KRAS mutational status, <span class="gene" id="22787409-3-288-291">ALK</span> rearrangements, and MET immunohistochemistry.